Castle Hook Partners LP purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 108,141 shares of the medical equipment provider’s stock, valued at approximately $53,126,000. Intuitive Surgical makes up about 1.0% of Castle Hook Partners LP’s portfolio, making the stock its 20th biggest holding.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ridgewood Investments LLC bought a new stake in Intuitive Surgical during the second quarter worth $26,000. Godsey & Gibb Inc. raised its position in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the period. LGT Financial Advisors LLC raised its position in shares of Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 54 shares during the period. MidAtlantic Capital Management Inc. bought a new position in shares of Intuitive Surgical in the third quarter valued at about $33,000. Finally, LRI Investments LLC bought a new position in shares of Intuitive Surgical in the first quarter valued at about $30,000. 83.64% of the stock is owned by institutional investors.
Intuitive Surgical Price Performance
Shares of NASDAQ ISRG opened at $538.55 on Thursday. The company has a 50 day simple moving average of $507.94 and a 200 day simple moving average of $466.79. The firm has a market cap of $191.82 billion, a PE ratio of 86.58, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $304.50 and a 1 year high of $552.00.
Insider Activity at Intuitive Surgical
In related news, CEO Gary S. Guthart sold 18,151 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the transaction, the chief executive officer now owns 24,219 shares in the company, valued at $12,391,166.97. This trade represents a 42.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jamie Samath sold 108 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the transaction, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This trade represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,459 shares of company stock worth $26,080,251 in the last quarter. 0.80% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the stock. Raymond James increased their price objective on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. BTIG Research raised their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup raised their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, Robert W. Baird raised their price target on shares of Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $526.06.
Get Our Latest Analysis on Intuitive Surgical
About Intuitive Surgical
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Featured Articles
- Five stocks we like better than Intuitive Surgical
- What Are Some of the Best Large-Cap Stocks to Buy?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Transportation Stocks Investing
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Insider Trading – What You Need to Know
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.